NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRXP NRX Pharmaceuticals Inc.

Market Closed 06-26 16:00:00 EDT

3.73

+0.17

+4.78%

盘后3.67

-0.06-1.61%

19:59 EDT

High3.87	Low3.49	Vol943.31K
Open3.52	D1 Closing3.56	Amplitude10.53%
Mkt Cap156.45M	Tradable Cap135.02M	Total Shares41.94M
T/O3.50M	T/O Rate2.61%	Tradable Shares36.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRXP","market":"US","secType":"STK","nameCN":"NRX Pharmaceuticals Inc.","latestPrice":3.73,"timestamp":1782504000000,"preClose":3.56,"halted":0,"volume":943311,"hourTrading":{"tag":"盘后","latestPrice":3.67,"preClose":3.73,"latestTime":"19:59 EDT","volume":5941,"amount":22115.0657,"timestamp":1782518368413,"change":-0.06,"changeRate":-0.016086,"amplitude":0.021314},"delay":0,"changeRate":0.04775280898876402,"floatShares":36197200,"shares":41943300,"eps":-0.966884,"marketStatus":"Market Closed","change":0.17,"latestTime":"06-26 16:00:00 EDT","open":3.52,"high":3.865,"low":3.49,"amount":3497837.6560419,"amplitude":0.105337,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.966884,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782720000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":3.56,"preHourTrading":{"tag":"盘前","latestPrice":3.513,"preClose":3.56,"latestTime":"09:09 EDT","volume":3727,"amount":13753.796551000001,"timestamp":1782479375733,"change":-0.047,"changeRate":-0.013202,"amplitude":0.103933},"postHourTrading":{"tag":"盘后","latestPrice":3.67,"preClose":3.73,"latestTime":"19:59 EDT","volume":5941,"amount":22115.0657,"timestamp":1782518368413,"change":-0.06,"changeRate":-0.016086,"amplitude":0.021314},"volumeRatio":0.7745425104527205,"impliedVol":2.4128,"impliedVolPercentile":0.9203},"requestUrl":"/m/hq/s/NRXP","defaultTab":"news","newsList":[{"id":"2646385379","title":"Nrx Pharmaceuticals Pushes Kadima Dispute into Arbitration Amid Acquisition Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2646385379","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646385379?lang=en_us&edition=fundamental","pubTime":"2026-06-26 04:01","pubTimestamp":1782417679,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals pushes Kadima dispute into arbitration amid acquisition lawsuitNRX Pharmaceuticals disclosed it has compelled arbitration with Kadima Neuropsychiatry Institute over a failed HOPE T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL15N3MZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B64PRP62.GBP","BK4588","IE00BGHQF748.EUR","SG9999014039.USD","IE00B3QW5Z07.USD","BK4112","IE00BKPKM429.USD","BK4007","IE00BN0W2V16.EUR","SG9999014005.SGD","IE00BN0W2W23.USD","NRXP","NDAQ","LU2210149790.SGD","BK4585","IE00BN0W2T93.GBP","SG9999014021.USD","LU0314104364.USD","SG9999014013.SGD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646385378","title":"NRX Pharmaceuticals - Initiates Arbitration with Kadima over Failed Closing Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2646385378","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646385378?lang=en_us&edition=fundamental","pubTime":"2026-06-26 04:01","pubTimestamp":1782417668,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nFWN42X0T4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646385347","title":"NRX Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2646385347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646385347?lang=en_us&edition=fundamental","pubTime":"2026-06-26 04:01","pubTimestamp":1782417668,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nFWN42X0T4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646238530","title":"NRX Pharmaceuticals: Co Does not Believe That Acquisition/non-acquisition of Any Individual Clinic Would be Material to Hope's Overall Business Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2646238530","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646238530?lang=en_us&edition=fundamental","pubTime":"2026-06-26 04:01","pubTimestamp":1782417668,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nFWN42X0T4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646436808","title":"H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646436808","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646436808?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:36","pubTimestamp":1782390990,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on NRX Pharmaceuticals, with a price target of $45.00. Tr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-nrx-pharmaceuticals-nrxp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-nrx-pharmaceuticals-nrxp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646728328","title":"Nrx Subsidiary HOPE Therapeutics Begins Patient Treatments Using Zeta Surgical TMS Navigation System","url":"https://stock-news.laohu8.com/highlight/detail?id=2646728328","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646728328?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:02","pubTimestamp":1782385355,"startTime":"0","endTime":"0","summary":"NRx subsidiary HOPE Therapeutics begins patient treatments using Zeta Surgical TMS navigation systemNRX Pharmaceuticals subsidiary HOPE Therapeutics began treating patients using Zeta Surgical’s FDA-c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL919kzx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","SG9999014013.SGD","LU0314104364.USD","NDAQ","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014039.USD","LU2210150020.SGD","NRXP","IE00BN0W2T93.GBP","SG9999014021.USD","LU2095319765.USD","IE00B3QW5Z07.USD","BK4588","BK4585","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646874700","title":"NRX Pharmaceuticals (nasdaq: Nrxp) Subsidiary Hope Therapeutics Treats First Patients Using Zeta Surgical's Fda-cleared Zeta Tms Navigation System","url":"https://stock-news.laohu8.com/highlight/detail?id=2646874700","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646874700?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:00","pubTimestamp":1782385229,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nFWN42W14V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646817039","title":"Kadima Neuropsychiatry Institute alleges NRx breached contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2646817039","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646817039?lang=en_us&edition=fundamental","pubTime":"2026-06-25 01:25","pubTimestamp":1782321915,"startTime":"0","endTime":"0","summary":"Kadima Neuropsychiatry Institute and its founder, Dr. David Feifel, said the have filed a complaint against NRx Pharmaceuticals (NRXP) in San Diego...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kadima-neuropsychiatry-institute-alleges-nrx-breached-contract-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kadima-neuropsychiatry-institute-alleges-nrx-breached-contract-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646381760","title":"Kadima Neuropsychiatry Institute Files Suit Against NRX Pharmaceuticals (nasdaq: Nrxp), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2646381760","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646381760?lang=en_us&edition=fundamental","pubTime":"2026-06-25 01:19","pubTimestamp":1782321545,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nFWN42W0SN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646179138","title":"Kadima Neuropsychiatry Institute: Lawsuit Seeks Specific Performance in Court Order Compelling Defendants to Close Deal on Terms in Executed Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2646179138","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646179138?lang=en_us&edition=fundamental","pubTime":"2026-06-25 01:19","pubTimestamp":1782321545,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nFWN42W0SN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646179008","title":"Kadima Neuropsychiatry Institute: Complaint Alleges NRX Warranted it Had Funds to Close While Concealing it Lacked Committed Financing for Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2646179008","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646179008?lang=en_us&edition=fundamental","pubTime":"2026-06-25 01:19","pubTimestamp":1782321545,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nFWN42W0SN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646781767","title":"Kadima Neuropsychiatry Institute Sues Nrx Pharma over Alleged Breach, Misrepresentation in Acquisition Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2646781767","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646781767?lang=en_us&edition=fundamental","pubTime":"2026-06-25 01:18","pubTimestamp":1782321499,"startTime":"0","endTime":"0","summary":"Kadima Neuropsychiatry Institute sues NRx Pharma over alleged breach, misrepresentation in acquisition dealKadima Neuropsychiatry Institute sued NRx Pharmaceuticals in San Diego County Superior Court ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDLK7hSg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645837155","title":"HOPE Therapeutics treats first patient using Zeta TMS Navigation System","url":"https://stock-news.laohu8.com/highlight/detail?id=2645837155","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645837155?lang=en_us&edition=fundamental","pubTime":"2026-06-23 23:05","pubTimestamp":1782227155,"startTime":"0","endTime":"0","summary":"HOPE Therapeutics, a unit of NRX Pharmaceuticals, treated its first patient using Zeta Surgical’s FDA-cleared Zeta TMS Navigation System.HOPE installed the system at clinics in Sarasota and West Palm Beach, with Zeta-navigated treatments starting this week at both sites.The platform uses RealTrack technology to align MRI or CT scans to facial anatomy in under two minutes, guiding TMS coil placement with sub-millimetric accuracy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL8WMlhh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645906837","title":"Zeta Surgical® Announces Successful Treatment of First Patient With Zeta Tms Navigation System at Hope Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2645906837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645906837?lang=en_us&edition=fundamental","pubTime":"2026-06-23 23:05","pubTimestamp":1782227131,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA4LBYHF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645488093","title":"Thomas Shrader Reiterates Buy on NRXP, Maintains $25 Price Target on NRX-100/101 FDA and RWE-Driven Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2645488093","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645488093?lang=en_us&edition=fundamental","pubTime":"2026-06-23 18:15","pubTimestamp":1782209744,"startTime":"0","endTime":"0","summary":"Thomas Shrader, an analyst from BTIG, maintained the Buy rating on NRX Pharmaceuticals. The associated price target remains the same with $25.00. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/thomas-shrader-reiterates-buy-on-nrxp-maintains-25-price-target-on-nrx-100-101-fda-and-rwe-driven-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/thomas-shrader-reiterates-buy-on-nrxp-maintains-25-price-target-on-nrx-100-101-fda-and-rwe-driven-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXP","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645502998","title":"NRx Pharma says FDA grants expanded access protocol for NRX-101 depression treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2645502998","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645502998?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126035,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals received FDA clearance for an expanded access protocol for NRX-101 to augment accelerated TMS in treatment-resistant depression.The program enables compassionate-use access for patients unable to enroll in the company’s pivotal SPARC-TMS trial.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLMTcLD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","SG9999014013.SGD","LU0314104364.USD","NDAQ","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014039.USD","LU2210150020.SGD","NRXP","IE00BN0W2T93.GBP","SG9999014021.USD","LU2095319765.USD","IE00B3QW5Z07.USD","BK4588","BK4585","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645610029","title":"NRX Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-Based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2645610029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645610029?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA9GN1D0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029953","title":"NRX Pharmaceuticals - to Charge Only Shipping and Data Costs for NRX-101 Under Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029953","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029953?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA9GN1D0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029614","title":"NRX Pharmaceuticals - Initiates Pivotal Trial of NRX-101 for Tms Augmentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029614","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029614?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA9GN1D0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641148249","title":"NRx notes real-world study showing IV ketamine beats nasal esketamine on depression remission, response rates","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148249","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641148249?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:50","pubTimestamp":1780663851,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals flagged results already presented in a peer-reviewed poster at the 2026 American Society of Clinical Psychopharmacology meeting.Real-world electronic health record analysis compared IV ketamine with intranasal esketamine in adults with treatment-resistant depression across community psychiatry clinics.IV ketamine showed higher rates of symptom improvement, response, and remission than intranasal esketamine in routine clinical care.Findings were limited by non-random treatment assignment, raising the risk that patient differences influenced outcomes.NRx highlighted the data as supportive of its IV ketamine program as it pursues a regulatory path that incorporates real-world evidence.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL43yzvR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4588","BK4112","SG9999014021.USD","BK4585","LU2210150020.SGD","LU2095319765.USD","IE00BN0W2V16.EUR","BK4007","SG9999014039.USD","SG9999014005.SGD","LU0314104364.USD","IE00BN0W2W23.USD","SG9999014013.SGD","NDAQ","LU2210149790.SGD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","NRXP","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.salbergco.com","stockEarnings":[{"period":"1week","weight":-0.0605},{"period":"1month","weight":-0.1285},{"period":"3month","weight":0.7032},{"period":"6month","weight":0.457},{"period":"1year","weight":0.0657},{"period":"ytd","weight":0.3764}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.074525},{"month":2,"riseRate":0.2,"avgChangeRate":-0.102766},{"month":3,"riseRate":0.4,"avgChangeRate":-0.034339},{"month":4,"riseRate":0.4,"avgChangeRate":-0.100305},{"month":5,"riseRate":0.8,"avgChangeRate":0.153649},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.164895},{"month":7,"riseRate":0.4,"avgChangeRate":0.039708},{"month":8,"riseRate":0.2,"avgChangeRate":-0.14211},{"month":9,"riseRate":0.4,"avgChangeRate":-0.012776},{"month":10,"riseRate":0.6,"avgChangeRate":0.037482},{"month":11,"riseRate":0.4,"avgChangeRate":0.048439},{"month":12,"riseRate":0.6,"avgChangeRate":0.121824}],"exchange":"NASDAQ","name":"NRX Pharmaceuticals Inc.","nameEN":"NRX Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NRX Pharmaceuticals Inc.,NRXP,NRX Pharmaceuticals Inc.股票,NRX Pharmaceuticals Inc.股票老虎,NRX Pharmaceuticals Inc.股票老虎国际,NRX Pharmaceuticals Inc.行情,NRX Pharmaceuticals Inc.股票行情,NRX Pharmaceuticals Inc.股价,NRX Pharmaceuticals Inc.股市,NRX Pharmaceuticals Inc.股票价格,NRX Pharmaceuticals Inc.股票交易,NRX Pharmaceuticals Inc.股票购买,NRX Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}